Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLLT1 | Q03111 | 20/20 | 0.63 |
| ▸ | MLLT3 | P42568 | 2/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | PIM1 | P11309 | 1/20 | 0.62 |
| ▸ | ACHE | P22303 | 1/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | TRIB2 | Q92519 | 1/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24376498 | 1.00 | MLLT1 (0.63) | MLLT1MLLT3CHRM2PIM1ACHE | |
| SCHEMBL24376413 | 1.00 | MLLT1 (0.63) | MLLT1MLLT3CHRM2PIM1ACHE | |
| SCHEMBL30293327 | 0.92 | MLLT1 (0.61) | MLLT1MLLT3CHRM2PIM1ACHE | |
| SCHEMBL29622426 | 0.91 | MLLT1 (0.65) | MLLT1MLLT3CHRM2PIM1ACHE | |
| SCHEMBL24376425 | 0.91 | MLLT1 (0.65) | MLLT1MLLT3CHRM2PIM1ACHE | |
| SCHEMBL29622114 | 0.91 | MLLT1 (0.65) | MLLT1MLLT3CHRM2PIM1ACHE | |
| SCHEMBL24376319 | 0.91 | MLLT1 (0.66) | MLLT1MLLT3CHRM2PIM1ACHE | |
| SCHEMBL24376457 | 0.91 | MLLT1 (0.65) | MLLT1MLLT3CHRM2PIM1ACHE | |
| SCHEMBL24376342 | 0.91 | MLLT1 (0.65) | MLLT1MLLT3CHRM2PIM1ACHE | |
| SCHEMBL24376374 | 0.90 | MLLT1 (0.64) | MLLT1MLLT3CHRM2PIM1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391765-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-12-07 | — | — | US | disclosed |
| WO-2023038500-A1 | COMPOUND FOR DEGRADING ENL PROTEIN AND MEDICAL USES THEREOF | 주식회사 유빅스테라퓨틱스 | 2023-03-16 | — | — | WO | disclosed |
| WO-2022086937-A9 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2022086937-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391765-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL | MLLT1, BCR, MCL1 | MLLT1 1/4885MLLT3 10/4885CHRM2 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.